# E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

> **NCT01133977** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 97 (actual)

## Conditions studied

- Stage IV Melanoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Lenvatinib
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01133977
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-11
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2016-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133977, "E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01133977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*